Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01842672 · ClinicalTrials.gov registry record · Phase 1
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
A Phase 1 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT01842672 is a Phase 1 study that has completed, run by New York Medical College. The registered enrollment target is 41 participants.
The verdict
NCT01842672, a Phase 1 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL).
Interventions
- DRUG Mitoxantrone
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-03 |
| Est. Completion | 2022-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01842672
The ClinicalTrials.gov registry entry for NCT01842672 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mitoxantrone is the first listed.
NCT01842672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01842672 about?
NCT01842672 is a clinical study titled "Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia". The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL).
What is the current status of trial NCT01842672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2013-03. Estimated completion is 2022-09.
What interventions are being tested in trial NCT01842672?
The interventions under investigation include: Mitoxantrone (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT01842672?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.